Innovation Pharmaceuticals Inc (IPIX)

[SitTight]

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection with a high mortality rate.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318821/#:~:text=Invasive%20pulmonary%20aspergillosis%20(IPA)%20is,receiving%20chemotherapy%20and%20immunosuppressive%20therapy.

In an A. fumigatus immunosuppressed mouse model in invasive pulmonary aspergillosis, Brilacidin plus CAS cleared infection in the lungs by almost 95 percent, compared to ~50 percent when each compound was administered individually.

http://www.ipharminc.com/press-release/2022/10/3/innovation-pharmaceuticals-announces-publication-of-scientific-article-on-the-antifungal-activity-of-brilacidin

Since Brilacidin was greenlighted for "compassionate use" by the FDA for Covid, why not apply for the same for IPA? There's no risk for the patients, but a tremendous chance of recovery.

Simply give IPA patients Brilacidin alongside CAS (both intravenously) and see what happens. We would get tremendously fast real results and we do not need Merck's approval or any deal with them. All we need for this is the FDA's expansion for "compassionate use" from Covid to IPA.